227 related articles for article (PubMed ID: 21111455)
1. Oncocytic carcinoma of the breast: frequency, morphology and follow-up.
Ragazzi M; de Biase D; Betts CM; Farnedi A; Ramadan SS; Tallini G; Reis-Filho JS; Eusebi V
Hum Pathol; 2011 Feb; 42(2):166-75. PubMed ID: 21111455
[TBL] [Abstract][Full Text] [Related]
2. Clinicopathologic significance of the basal-like subtype of breast cancer: a comparison with hormone receptor and Her2/neu-overexpressing phenotypes.
Kim MJ; Ro JY; Ahn SH; Kim HH; Kim SB; Gong G
Hum Pathol; 2006 Sep; 37(9):1217-26. PubMed ID: 16938528
[TBL] [Abstract][Full Text] [Related]
3. Oncocytic adrenocortical carcinomas: a pathological and immunohistochemical study of four cases in comparison with conventional adrenocortical carcinomas.
Song SY; Park S; Kim SR; Suh YL
Pathol Int; 2004 Aug; 54(8):603-10. PubMed ID: 15260851
[TBL] [Abstract][Full Text] [Related]
4. Genomic profiling of mitochondrion-rich breast carcinoma: chromosomal changes may be relevant for mitochondria accumulation and tumour biology.
Geyer FC; de Biase D; Lambros MB; Ragazzi M; Lopez-Garcia MA; Natrajan R; Mackay A; Kurelac I; Gasparre G; Ashworth A; Eusebi V; Reis-Filho JS; Tallini G
Breast Cancer Res Treat; 2012 Feb; 132(1):15-28. PubMed ID: 21509527
[TBL] [Abstract][Full Text] [Related]
5. Clinical, histopathologic, and immunohistochemical features of microglandular adenosis and transition into in situ and invasive carcinoma.
Khalifeh IM; Albarracin C; Diaz LK; Symmans FW; Edgerton ME; Hwang RF; Sneige N
Am J Surg Pathol; 2008 Apr; 32(4):544-52. PubMed ID: 18300793
[TBL] [Abstract][Full Text] [Related]
6. Morphological and immunophenotypic analysis of breast carcinomas with basal and myoepithelial differentiation.
Rakha EA; Putti TC; Abd El-Rehim DM; Paish C; Green AR; Powe DG; Lee AH; Robertson JF; Ellis IO
J Pathol; 2006 Mar; 208(4):495-506. PubMed ID: 16429394
[TBL] [Abstract][Full Text] [Related]
7. Male breast carcinoma: an evaluation of prognostic factors contributing to a poorer outcome.
Joshi MG; Lee AK; Loda M; Camus MG; Pedersen C; Heatley GJ; Hughes KS
Cancer; 1996 Feb; 77(3):490-8. PubMed ID: 8630956
[TBL] [Abstract][Full Text] [Related]
8. Immunohistochemical identification of basal-type cytokeratins in invasive ductal breast carcinoma--relation with grade, stage, estrogen receptor and HER2.
Kusińska R; Potemski P; Jesionek-Kupnicka D; Kordek R
Pol J Pathol; 2005; 56(3):107-10. PubMed ID: 16334976
[TBL] [Abstract][Full Text] [Related]
9. The role of HER2/neu overexpression/amplification in the progression of ductal carcinoma in situ to invasive carcinoma of the breast.
Latta EK; Tjan S; Parkes RK; O'Malley FP
Mod Pathol; 2002 Dec; 15(12):1318-25. PubMed ID: 12481013
[TBL] [Abstract][Full Text] [Related]
10. Bone metastasis is strongly associated with estrogen receptor-positive/progesterone receptor-negative breast carcinomas.
Wei B; Wang J; Bourne P; Yang Q; Hicks D; Bu H; Tang P
Hum Pathol; 2008 Dec; 39(12):1809-15. PubMed ID: 18715613
[TBL] [Abstract][Full Text] [Related]
11. Aneuploidy in oncocytic lesions of the thyroid gland: diffuse accumulation of mitochondria within the cell is associated with trisomy 7 and progressive numerical chromosomal alterations.
Dettori T; Frau DV; Lai ML; Mariotti S; Uccheddu A; Daniele GM; Tallini G; Faa G; Vanni R
Genes Chromosomes Cancer; 2003 Sep; 38(1):22-31. PubMed ID: 12874783
[TBL] [Abstract][Full Text] [Related]
12. Expression of cytokeratin markers, ER-alpha, PR, HER-2/neu, and EGFR in pure ductal carcinoma in situ (DCIS) and DCIS with co-existing invasive ductal carcinoma (IDC) of the breast.
Steinman S; Wang J; Bourne P; Yang Q; Tang P
Ann Clin Lab Sci; 2007; 37(2):127-34. PubMed ID: 17522367
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of oestrogen and progesterone receptor status in HER-2 positive breast carcinomas and correlation with outcome.
Francis G; Beadle G; Thomas S; Mengersen K; Stein S
Pathology; 2006 Oct; 38(5):391-8. PubMed ID: 17008275
[TBL] [Abstract][Full Text] [Related]
14. Expression and possible prognostic role of MAGE-A4, NY-ESO-1, and HER-2 antigens in women with relapsing invasive ductal breast cancer: retrospective immunohistochemical study.
Bandić D; Juretić A; Sarcević B; Separović V; Kujundzić-Tiljak M; Hudolin T; Spagnoli GC; Cović D; Samija M
Croat Med J; 2006 Feb; 47(1):32-41. PubMed ID: 16489695
[TBL] [Abstract][Full Text] [Related]
15. Oncocytic adrenocortical neoplasms--a clinicopathologic study of 13 new cases emphasizing the importance of their recognition.
Wong DD; Spagnolo DV; Bisceglia M; Havlat M; McCallum D; Platten MA
Hum Pathol; 2011 Apr; 42(4):489-99. PubMed ID: 21237489
[TBL] [Abstract][Full Text] [Related]
16. Prognostic value of proliferating cell nuclear antigen (PCNA) in infiltrating ductal carcinoma breast.
Aziz SA; Pervez S; Khan SM; Kayani N; Nasir MI
J Coll Physicians Surg Pak; 2005 Apr; 15(4):225-9. PubMed ID: 15857596
[TBL] [Abstract][Full Text] [Related]
17. Clinicopathologic characteristics and prognosis of glycogen-rich clear cell carcinoma of the breast.
Ma X; Han Y; Fan Y; Cao X; Wang X
Breast J; 2014; 20(2):166-73. PubMed ID: 24400866
[TBL] [Abstract][Full Text] [Related]
18. Breast carcinoma in pregnant women: assessment of clinicopathologic and immunohistochemical features.
Middleton LP; Amin M; Gwyn K; Theriault R; Sahin A
Cancer; 2003 Sep; 98(5):1055-60. PubMed ID: 12942575
[TBL] [Abstract][Full Text] [Related]
19. Oncocytic versus mitochondrion-rich follicular thyroid tumours: should we make a difference?
Tsybrovskyy O; Rössmann-Tsybrovskyy M
Histopathology; 2009 Dec; 55(6):665-82. PubMed ID: 20002768
[TBL] [Abstract][Full Text] [Related]
20. Comparative study of two androgen-induced markers (apolipoprotein D and pepsinogen C) in female and male breast carcinoma.
Serra C; Vizoso F; Lamelas ML; Rodríguez JC; González LO; Merino AM; Baltasar A; Pérez-Vázquez MT; Medrano J
Int J Surg Investig; 2000; 2(3):183-92. PubMed ID: 12678518
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
